Cargando…
Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients
BACKGROUND: Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed that use...
Autores principales: | Yamamoto, Haruko, Hamasaki, Toshimitsu, Onda, Kaori, Nojiri, Takashi, Aragaki, Masato, Horie, Nao, Sato, Norihiro, Hida, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907139/ https://www.ncbi.nlm.nih.gov/pubmed/31829248 http://dx.doi.org/10.1186/s13063-019-3904-4 |
Ejemplares similares
-
A case of ultrashort‐acting beta‐blocker landiolol hydrochloride for takotsubo syndrome with left ventricular outflow tract obstruction
por: Takama, Takuro, et al.
Publicado: (2018) -
Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
por: Wada, Yuko, et al.
Publicado: (2016) -
Dose-dependent scavenging activity of the ultra-short-acting β1-blocker landiolol against specific free radicals
por: Matsumoto, Shigekiyo, et al.
Publicado: (2022) -
Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β(1)-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients
por: Taenaka, Nobuyuki, et al.
Publicado: (2013) -
A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial
por: Nojiri, Takashi, et al.
Publicado: (2017)